Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ariad’s Iclusig Cleared For European Approval By CHMP

This article was originally published in The Pink Sheet Daily

Executive Summary

Europe's top scientific advisory panel, CHMP, granted positive opinions for Ariad's new leukemia therapy Iclusig, Gilead's four-drug HIV therapy, Stribild and Baxter's subcutaneous IgG formulation, HyQvia, at its March 2013 meeting,

You may also be interested in...



HyQvia Needs Provider, Patient Education, Not Population Restrictions, Panel Says

CBER’s Blood Products Advisory Committee votes in favor of communication strategies to mitigate the risks of Baxter’s primary immune deficiency treatment but not to monitor for possible adverse events associated with long-term exposure.

Baxter’s HyQvia Rises Above FDA’s Theoretical Long-Term Concerns

Agency officials say long-term immunogenicity issues could manifest among patients taking proposed primary immunodeficiency disorder treatment, but advisory committee concludes risk can be managed.

Sanofi’s Aubagio And Biogen Idec’s Tecfidera Make It A Good Day For MS Sufferers At EMA

The EMA’s CHMP has given the nod to Sanofi’s Aubagio and Biogen Idec’s Tecfidera for multiple sclerosis, setting the scene for a European three-way battle with Novartis’ Gilenya in the coming months.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS075433

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel